Clinical trials
Completed Dyslipidemias trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
790 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 7 |
| 2001 | 5 |
| 2002 | 9 |
| 2003 | 21 |
| 2004 | 26 |
| 2005 | 38 |
| 2006 | 53 |
| 2007 | 42 |
| 2008 | 48 |
| 2009 | 29 |
| 2010 | 34 |
| 2011 | 42 |
| 2012 | 34 |
| 2013 | 28 |
| 2014 | 44 |
| 2015 | 28 |
| 2016 | 39 |
| 2017 | 33 |
| 2018 | 32 |
| 2019 | 35 |
| 2020 | 19 |
| 2021 | 36 |
| 2022 | 24 |
| 2023 | 27 |
| 2024 | 22 |
| 2025 | 18 |
| 2026 | 9 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 790 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 51 |
| Chong Kun Dang Pharmaceutical | 37 |
| Takeda | 36 |
| Merck Sharp & Dohme LLC | 16 |
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 15 |
| Abbott | 11 |
| Pfizer | 11 |
| UCSF Benioff Children's Hospital Oakland | 10 |
| Eli Lilly and Company | 9 |
| Kowa Research Europe | 9 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Dyslipidemias | 790 |
| Hypertension | 153 |
| Diabetes Mellitus | 112 |
| Hypercholesterolemia | 110 |
| Diabetes Mellitus, Type 2 | 102 |
| Obesity | 100 |
| Cardiovascular Diseases | 70 |
| Hyperlipidemias | 69 |
| Metabolic Syndrome | 61 |
| Insulin Resistance | 48 |
Trials
Showing 76 to 100 of 790. Each trial links to its page on Pharma Observatory.
690 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.